Fusion protein having triple activity and use thereof
AssigneeShanghai Minwei Biotechnology Co., LTD
InventorsWeiyue Han, Guitao Zhang, Dixiang Luo, Wenxin Song, Shaodong Zhong, Dan Liu, Jiangtao Peng
Life of this patent
Estimating the term…
Abstract
A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.
Claims26
A polypeptide comprising the amino acid sequence of any one of SEQ ID NOS:
- 8, 10, 18, and 19.
A polypeptide comprising a mutant human FGF21 amino acid sequence comprising valine at position 19, arginine at position 98, asparagine at position 171, threonine at position 173, serine at position 167 and arginine at position 175, wherein the amino acid position numbering is relative to the FGF21 amino acid sequence set forth in SEQ ID NO:
- 1.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.